T-Therapeutics is a next-generation TCR company, spun out from the University of Cambridge, deeply rooted in world-leading academic science. We are developing ‘optimal’ TCR based therapeutics using our proprietary OpTiMus® platform, based on a fully humanized TCR mouse that provides an almost unlimited source of unique, antigen-specific human TCRs. We combine world-leading expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. biotechnology, research, T cell, biologics, and science

211 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing Cancer Treatment Breakthroughs Carcinotech provides comprehensive solid tumor research services to advance drug development and enhance personalized therapy decisions. At the heart of its offerings is the proprietary Carcino3DTM bioprinting technology, which creates assay-ready, 3D tumors derived from patient biopsies. This innovative, translational approach delivers a predictive in vitro model, generating critical insights into therapeutic efficacy, and treatment optimization. Cancer research, 3D bioprinting , Cancer microenvironment, drug testing, oncology, assay services, oncology pre-clinical services, solid tumours, solid tumors, tumour microenvironment, tumor microenvironment, early phase drug development, and early drug discovery

274 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

The synthetic collagen revolution NVH Medicinal world expert in synthetic collagen NVH Medicinal is a biotechnology company based in Dijon, created at the end of 2008 whose mission is based on the treatment of pathologies linked to a collagen deficiency. It develops products derived from collagen, the most abundant protein in the body and whose dysfunctions cause numerous diseases (aging, cardiovascular, inflammatory, neurological diseases, fibrosis, cancer and rare diseases). NVH's ambition is to be recognized as an innovative player in the treatment of collagen-related diseases by becoming one of the world leaders in the development, production and marketing of a …

77 similar entities Type: Startup Activities: deeptech manufacturing Technologies: Synthetic Biology

Pioneering RNA cell therapy for autoimmune disease Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis with plans to initiate a Phase 2 trial in myositis. For more information, please visit www.cartesiantherapeutics.com. Immunotherapy, Oncology, Molecular Biology, Immunology, Myasthenia Gravis, ARDS, Cell Therapy, NETs, Gene Therapy, Cancer Research, multiple myeloma, SLE, mRNA, CAR-T, Systemic lupus erythematosus, Autoimmunity, Autoimmune Disease, and Lupus

293 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Rewriting the rules of drug creation Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas …

219 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

Driven by the heart We officially combined with Bristol Myers Squibb to further strengthen our scientific capabilities and treatments for cardiovascular patients. Visit www.bms.com to learn more about our work to produce the next generation of medicines for patients with serious cardiovascular disease. For more information on the acquisition, see our press release at: https://one.bms.com/40FsT7W Genetic Heart Disease, Cardiomyopathy, biotechnology, cardiovascular disease, heart failure, precision medicine, therapeutics, drug discovery, drug development, and R&D

Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

Biotech Company 100% Focused on Pediatric Cancer Drug Development A life science company exclusively focused on finding cures for childhood cancer by identifying and developing the most promising projects to create new treatments and drugs. drug development, clinical development, and childhood cancer

170 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Changing lives of neuromuscular patients with gene therapy. Atamyo Therapeutics is focused on the development of a new generation of safe and effective gene therapies for neuromuscular diseases. A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon. Atamyo’s most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD). The name of the company is derived from two words: Celtic Atao which means “Always” or “Forever” and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Exploring together! We support biopharmaceutical research with translational preclinical models. CYNBIOSE is France-based non-clinical research organization. Preclinical CRO, Pharmacokinetics, POC, Efficacy, Immunotherapies, Drug, Early tox, CNS, Infectious diseases, Respiratory diseases, Non clinical, CRO, PK, PD, and TK

165 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A cell-therapy technology company developing artificial membrane-binding proteins for oncology and regenerative medicine CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation advanced therapies. Our novel cell membrane augmentation technology enables us to add new functionalities to various therapeutic cells. CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer. We are looking to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health. Biochemistry, Immunology, Oncology, Regenerative Medicine, Cell therapies, and Proteins

121 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering drug discovery company exploiting cutting edge technologies to create best-in-class small molecule medicines C4XD is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge technologies to efficiently deliver world‐leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced molecular design and patient stratification capabilities, generating small molecule drug candidates across multiple disease indications focused on immuno-inflammation. The Company was founded as a spin-out from the University of Manchester. It has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4XD …

295 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We accompany companies with a complete service of Preclinical Trials and Clinical Trials of safety and efficacy GOYA INNOVA is a Spanish laboratory with 50 years of experience, specialized in preclinical and clinical evaluations of safety and efficacy for cosmetic, health products and food supplements.⁣ We manage 55,000 samples annually, and with our partners, we offer a comprehensive service.⁣ Our differential model of preclinical and clinical research integrates a CRO with its own Medical and Medical-Aesthetic Center.⁣ With more than 40 doctors of different specialties, we can:⁣ • Carry out studies under the highest quality standards⁣ • Optimize costs and …

289 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

Late clinical stage company focused on drug discovery and development for the treatments of rare disorders of the CNS For additional information: info@sombiotech.com Pre-clinical validation, Licensing, In silico screening, Rare Diseases, Drug repurposing, Orphan CNS indications, Central Nervous System, Intellectual Property, and Artificial Intelligence

288 similar entities Type: Startup Activities: biotech deeptech legaltech Technologies: A.I. Synthetic Biology

Myomo, Inc. is a medical device company specializing in myoelectric technology to enhance mobility for individuals with neurological disorders and upper-limb paralysis. We design and market the MyoPro®, a non-invasive, powered arm brace (orthosis) that helps people regain functional use of their arms and hands after a stroke, brachial plexus injury (BPI), traumatic brain injury (TBI), spinal cord injury, or conditions like multiple sclerosis (MS). By detecting a user’s own muscle signals through sensors on the skin, the MyoPro® assists movement, empowering users to perform daily tasks and improve their quality of life. It is the only device of its …

93 similar entities Type: SMB Activities: deeptech healthtech Technologies: Synthetic Biology

Let's Build Better Cells Together At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQureTM gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we’ve been advancing cell engineering, shaping …

334 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Standard BioTools delivers the leading proteomic and multi-omic solutions that enable researchers to discover unique biological insights not accessible by other technologies. Mass Cytometry, Tissue Imaging, NGS Library Prep, Genotyping, Gene Expression, Copy Number Variation, Real-Time PCR, and Single-Cell Genomics

264 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Targeted treatment of serious infections mycoBiologics is a University of Aberdeen biotech spinout company which is dedicated to developing new antibody therapies to improve the survival of patients suffering from life-threatening, drug-resistant infections. Antibody therapy, Anti-infectives, Antifungal, Antibacterial, and Drug discovery

298 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Generate human-specific efficacy and safety data with PhysioMimix® microphysiological systems. CN Bio is a leading Organ-on-a-chip (OOC) company that enables scientists to improve the accuracy and efficiency of preclinical drug discovery. Our PhysioMimix® Core microphysiological system, 3D-validated cells, consumable plates, and Contract Research Services facilitate the prediction of human responses to drug exposure, in the presence or absence of disease, so that new medicines can be brought to market more rapidly, cost-effectively and using fewer animals. Utilizing primary cells, our perfused single (Lung, Liver), and multi-organ (Gut/Liver, Lung/Liver) models recapitulate the microarchitecture, microenvironment, and function of their human counterparts in …

202 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Cellesce specialises in the development, scale up and manufacture of PDOs (patient-derived organoids) Cellesce Ltd is a biochemical engineering company based in Cardiff in the UK. Cellesce specialises in the development, scale up and manufacture of organoids (PDOs). Cell expansion, Organoid culture, Drug discovery, Oncology, Bioprocess, and 3D Cell Culture

86 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Dynacure is a clinical-stage company focused on developing novel therapies for rare diseases. Dynacure is a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Dynacure is developing DYN101, an investigational antisense product candidate designed to reduce the expression of dynamin 2 protein for the treatment of Myotubular and Centronuclear Myopathies, in strategic collaboration with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders, including its DYN201 program for the treatment of Hereditary Spastic Paraplegias. Dynacure is headquartered in …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Your Cell-Therapy Specialized CDMO Cell-Easy is a CDMO specialized in Cell Therapy. We support biotech, pharma, and public institutions with GMP development and manufacturing. Our mission: accelerate your Cell Therapy’s path to market, with patient access as our priority. ATMPs are not conventional biologics — they are living drugs. Our team brings hands-on expertise in cell culture across all cell types, engineered or not, addressing challenges in development, GMP manufacturing, and QC. Beyond core CDMO services — process diagnostics, development, GMP production, cell banking, cryostorage, and delivery — we also support sourcing of human biological materials and clinical trial setup, …

200 similar entities Type: Startup Activities: biotech healthtech manufacturing Technologies: Synthetic Biology

Created in 2017, Cyprio is founded on ten years of research at the prestigious French institute for higher education in science and engineering, Ecole Supérieure de Physique et Chimie Industrielles de la ville de Paris (ESPCI Paris), with a strong expertise in the field of 3D cell culture, liver biology and drug development. This makes Cyprio the holder of a unique technology for fabrication of alginate liquid-core capsules containing 3D cellular models physiologically more relevant than traditional monolayer cell culture and compatible with high throughput screening applications. Our first product "HepatoPearl" has been validated as a beneficial in vitro liver …

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Discover your favorite frequencies to boost your drug discovery business CellSine provides devices and software that make advanced electrochemical impedance spectroscopy easily accessible to any microbiological researcher. It delivers a platform tool for a that enables a wide variety of biochemical studies. Biotechnology, Cell culture monitoring, Proteïn - Proteïn interactions, Suspension cultures, Receptor signaling, Biofilm maturation, and T lymphocyte activation

380 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Follow us at Shionogi Inc. for news about our rare disease research programs https://www.linkedin.com/company/shionogi-inc-/ drug discovery, PDE4D, PDE4B, Fragile X, CTE, Rubinstein-Taybi, traumatic brain injury, Clinical Trials, Fragile X syndrome, Cognition, BPN14770, and Memory Loss

364 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Chemical tools for bioconjugaison & biodrugs McSAF is a Deeptech company specialized in Bio-Organic & Bio-Conjugates Chemistry, developing innovative technologies for improved targeted therapies. Its core expertise covers Therapeutic Peptides and Proteins, Antibodies, and Drug Conjugates. The team has a strong background in synthetic selective chemistry, and a real expertise in bioconjugation, including specific designs of Antibody Drug Conjugates (ADCs) with own proprietary coupling technology. Plus, the company has now a pipeline of three products in oncology incorporating McSAF Inside technology with the ambition to bring new biodrugs on the market solving unmet medical needs. Bioconjugation, Biopharmaceuticals, Antibody Drug Conjugates, …

135 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Accelerate drug development for neurological diseases SYNAXYS is French biotech specialized in the characterization of the response of the nervous system for nutraceutic, pharmaceutic and veterinary applications. We offer a complete range of R&D services to support drug development, from defining the dose effects in a human model, to identify biological targets and action mechanism, acute and chronic toxicity, or comparison to established treatments. Our field of application: - Drug positioning - Therapeutic evaluation in a diease model - Neuro-oncology - Data generation for IA modeling Neuro-engineering, Neuronal diseases modeling, Neuro-oncology, Autism, Alzheimer disease, and Glioblastoma

204 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leading preclinical CRO specializing in metabolic disorders. Physiogenex is a leading preclinical research organization (CRO) specializing in metabolic disorders such as diabetes, insulin resistance, obesity, fatty liver (NASH / NAFLD), dyslipidemia, atherosclerosis and cardiovascular complications. We provide: - Classical and proprietary diet-induced in vivo models - Innovative in-house techniques (RCT) and gold standard methods (glucose clamps with radiolabelled tracers, ...) - In vivo preclinical imaging services Our models and technologies are customized and we deliver unparalleled scientific expertise for R&D, preclinical development, post-marketing studies and drug repositioning. We provide both the biopharmaceutical and nutraceutical companies with optimal and reliable solutions …

83 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking New Targets to Transform the Treatment of Neurodegenerative Diseases Unlocking New Targets to Transform the Treatment of Neurodegenerative Diseases neurodegeneration, RNA therapeutics, physiological upregulation, post-transcriptional upregulation, mRNA, ASO, and SINEUP

209 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

European Mammalian CRDMO - From Discovery mgs to Clinical GMP kgs. Icosagen is a unique European CRDMO, being successfully in the business for more than 26 years as an independent family-owned company. As such, we combine pre-clinical CRO and clinical CDMO development expertise at one single site for therapeutic antibodies, multispecifics, ADCs, and other complex recombinant protein drug candidates. As a CRDMO we discover, develop, and manufacture proteins seamlessly from research concepts into pre-clinical and clinical development stages. This includes everything from small-scale transient productions to stable high producing cell lines, to manufacture clinical GMP materials in our modern 200/1000L …

71 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Antineo aims to accompany customers in the preclinical development of novel anticancer agents. We provide services and strategic advice for preclinical development, optimal choice of in vitro and in vivo models as well as strategic input on potential indications to target in the therapeutic landscape. Développement préclinique, in vitro, ex vivo, in vivo, Preuve de concept, Expertise scientifique en pharmacologie, and Modèles à façon

223 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Building a sustainable sector and accelerate the discovery of new treatments tailored to each patient. French consortium to develop new experimental models of cancer in 9 cancer pathologies of interest (Lung, Pancreas, Breast, Liver, Ovary...) 3 major R&D axes: - Developing in vivo models and cell-based assays - Mimicking the human biology by humanizing the tumor microenvironment in mice - Studying the microbiota in cancer patients Oncology, Cancer research, Patient derived Xenograft, Cell lines, Ex vivo assays, Microbiota, Data mining , Translationnal medecine, Humanized mice, Biomarker, Research and Development, In vivo models, Ex vivo models, and Cancer

264 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Cytocybernetics specializes in cellular electrophysiology. We developed the Cybercyte, which is a very powerful, but user friendly, plug and play dynamic clamp system. We offer a complete range of CRO services, including FDA mandated drug safety screening, custom electrophysiology, custom modelling, and custom analysis. Electrophysiology, Dynamic Clamp, and Drug Safety Screening

96 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Neocor is dedicated to pioneering transformative therapies in cardiac care We are currently developing a novel gene therapy approach targeting ischemic and rare genetic cardiac diseases, and moving from lab preclinical trials to regulatory trials. The Company was founded in October and has received strong traction since inception. We will be looking to strengthen our human and financial ressources in the coming month in order to start the regulatory pre clinical trials. gene therapy, biotechnology, rare disease, and cardiology

337 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Smartox Biotechnology is specialized in peptide research and manufacturing Smartox Biotechnology is specialized in peptide research and engineering. Peptide synthesis, physiology, pharmacology, neuroscience, ion channel research, toxin, venomous animals, and screening library

297 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Making cell therapies more durable and effective through metabolic reprograming. At MPC Therapeutics, we are convinced that mitochondria, the small organelles at the core of the cell's metabolism, represent untapped therapeutic targets. Headquartered in Switzerland, our startup is focused on cellular rejuvenation to improve the performance of cell therapies and treat degenerative pathologies. Our novel approach uses proprietary first-in-class small molecules that specifically target mitochondria to trigger metabolic reprogramming. Visit our website for more info. Longevity, Mitochondria, Cellular rejuvenation, Immunotherapy, and CAR T cell therapy

80 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Guiding the body to heal itself VIVOLTA is the healthcare industry’s trusted partner for contract development and manufacturing of electrospun medical products that guide the body to heal itself. Founded in 2008, we leverage our proud heritage as high-performance electrospinning equipment designer now as a leading CDMO for electrospun medical devices and drug delivery systems. Electrospinning, Nanotechnology, Biomaterials, MedTech, Medical Devices, Tissue Engineering Scaffolds, Medical Solutions, Polymers, Nanofibers, GMP, Scalable Manufacturing, Co-Development, Regenerative Medicine, Drug Delivery Solutions, Nanofibers, Tissue Engineering, Medical Electrospinning, Cardiovascular Devices, Sports Medicine Devices, General Surgery Soft Tissue Reconstruction, and MediSpin

108 similar entities Type: SMB Activities: manufacturing deeptech healthtech Technologies: Synthetic Biology

Regain control with personalized muscle regeneration MUVON Therapeutics is a clinical stage Life Science spin-off from the University of Zurich developing a therapeutic platform for the regeneration of skeletal muscle tissue based on autologous cells, not only repairing damaged tissue but also increasing the regenerative potential of weakened muscles. Our initial area of focus is the treatment of stress urinary incontinence in women, supporting them respectfully throughout their journey to a healthy life.

85 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies

630 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We are your responsive, reliable, and resourceful CDMO Partner. Streamline your biomanufacturing programs with Cytovance Biologics! Born from a decades-long history in drug development, we believe in creating a healthier world where every biologic’s path to commercialization is advanced by a CDMO partner that delivers ingenuity end-to-end. Whether your large molecule product needs the flexibility of a customized approach or the efficiency of a predetermined platform process, Team Cytovance has the deep expertise in microbial and mammalian expression systems to support your scale-up at every stage. From early needs like cell line development and strain selection to cGMP manufacturing for …

192 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Empowering Muscle Empowering Lives Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Heart Failure and Hypertrophic Cardiomyopathy

68 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Treating cancer with γδ T cells | Nasdaq Ticker - $TCBP TC BioPharm is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. We have a growing team based in our Glasgow office, alongside a wide range of scientific advisors, and partner organisations. Clinical Grade Cell Therapy, Cancer Immonotherapy, Regenerative Medicine, and Stratified Medicine

348 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ncardia believes that human stem cell (iPSCs) technologies will bring better therapies to patients faster. Ncardia is a drug discovery company and expert in human iPSC technology. We operate worldwide with facilities, offices and staff throughout Europe and North America. We work with biopharmaceutical companies in drug discovery worldwide, to leverage the power of stem cell technologies in the development of novel therapies of multiple modalities at any stage of development. Over the past 10 years, we have built the expertise and infrastructure required to differentiate, manufacture and characterize high-quality iPSC-derived cell and disease models. We can facilitate the process …

424 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Your partner in uro-genital pre-clinical research UROSPHERE is a leading Contract Research Organization specializing in preclinical urogenital, gastro-intestinal and oncological pharmacology studies. We provide the pharmaceutical and biopharmaceutical industries with a unique experimental research platform combining both in vivo models and in vitro assays on human and animal tissues. Innovation, Uro-genital pathologies, Oncology, PDX models, Organoids, CRO, Preclinical Research, Pharmacology, Drug development, Gastrointestinal pathologies, Experimental models, Pain, and Inflammation

165 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Transforming lives with groundbreaking treatments Coultreon Biopharma's mission (formerly Onco3R Therapeutics) is to develop life-changing medicines for patients affected by chronic inflammatory diseases of high unmet medical needs. The team is leveraging their knowledge and expertise to bring transformative innovations to patients suffering from auto-immune diseases. In this field, there is an urgent need for more convenient oral drugs that can offer greater efficacy with a better safety profile. Drug Discovery, Drug Development, Immunology, Biotech, and R&D

826 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies. Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics

296 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

In vitro Slice Electrophysiology for CNS and Pain Research Neuroservice USA has been acquired by Neuroservices Alliance Please visit: https://www.linkedin.com/company/18799325 Drug Discovery, CNS, Electrophysiology, Pharmacology, Multi-Electrode Array, Patch-Clamp, Pain, Brain slices recordings, Safety, Toxicology, Neuropharmacology, CNS Research, CNS Preclinical Research, Preclinical Research, and CNS Electrophysiology

139 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Global Leaders in Mammalian Cell Line Development KBI Biopharma and Selexis SA are consolidating operations as one organization under the KBI Biopharma name. This streamlined approach supports customers in accelerating drug development and manufacturing, creating greater flexibility, efficiencies, and a simplified partner experience. You can follow us on the KBI Biopharma page to stay up-to-date on the latest news, events, and happenings. Cell Line Development, HTS, Cell Line Engineering, Contract Biological Services, Stable Cell Line Development, Cell Engineering, Variant Screening, Research Cell Banks, Monoclonal Antibodies, Whole Genome Sequencing, Bispecific Antibodies, CDMO, Monoclonality Assessment, Biotechnology, Biosimilars, Cell line engineering, Genetic engineering, …

589 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Accelerating global drug development Cytochroma predict how drugs will react in a global population in health or disease. Our unique, ethnically diverse library of iPSC and automated cell culture generates robust, reliable, mature hepatocytes for toxicity testing. We are supporting life science companies, de-risking safe compounds prior to clinical testing, making new drug development faster, safer and more efficient. toxicity testing, liver specialists, hepatocyte testing, disease models, high throughput, high content screening, iPSC, automated manufacture, machine learning, artificial intelligence, predictive testing, and pre clinical testing

180 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology

Develop human organ models with true physiological complexity We are specialized in the production and development of human, immunocompetent Organ-on-Chip technology for in vitro disease and infection modelling. Organ-on-Chip, Human Cell Biology, Infection, Infectious disease, Toxicity profiling, Immune Cell Interactions, Inflammatory Diseases, Antibody recycling, and Uptake / Transport studies

263 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

Plasticell is a biotechnology company that develops novel therapies through precise manipulation of stem cells and more differentiated cell types using award-winning combinatorial screening technology. Technolgy Innovate cell-based combinatorial screening technology allows us to develop optimised protocols for cell expansion, cell differentiation, gene transduction, biomolecule production as well as the provision of human cells for use in drug discovery. Pipeline Out therapeutic projects include advanced cell and gene therapies as well as drugs discovered by screening rare human cell types derived from stem cells Visit our website www.plasticell.co.uk for more details. Stem Cell Research, Biotechnology, and High Throughput Stemcell Research

180 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Activating RNA, mastering disease Harnessing an innate mechanism of gene activation, MiNA Therapeutics'​ platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver and other diseases. Gene activation, RNA therapeutics, Liver disease, and Drug discovery

228 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Accelerate and secure your pipeline with preclinical expertise. in vitro & in vivo pharmacology services since 1991. ETAP-LAB – Preclinical CRO supporting therapeutic innovations for over 35 years ETAP-LAB is a recognized European preclinical CRO delivering efficient, cost-effective services to pharmaceutical, biotech/medtech, and nutraceutical companies across four key areas of expertise: • BRAINXPLORE – Expert in neurology and CNS disorders with integrated preclinical solutions for neurodegeneration and behavioral pharmacology. ​​ • SKINAXIS – Pharmacology efficacy in dermatology and skin disorders – supporting the development of drugs, regenerative therapies, and medical devices – with a strong track record of successful market …

104 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

BioCytex is a contract research organization specializing in biomarker detection and analysis of normal and pathological cells in whole blood, bone marrow and other tissue samples. With over 20 years of experience in flow cytometry, we have a wide range of experience in developing and validating assays to suit many different requirements including immunophenotyping, detection of intracellular / extracellular markers, antigen binding assays. With the capacity to simultaneously measure multiple parameters on hundreds of individual cells per second, flow cytometry is a powerful technology with a wide variety of applications in pharmaceutical development. BioCytex is working with worldwide pharmaceutical companies. …

79 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

The Cell Therapy Venture Builder MedXCell is a European cell therapy venture builder with a strong industrial mindset and a global perspective. Our focus is on technologies, techniques or novel applications in major diseases such as cancer, autoimmune, neurological and degenerative disorders. Established in 2018, we have offices in Switzerland, the EU (France) and the US (Cambridge, MA) and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development and funding capabilities. Biotechnology, Cell Therapy, Immunotherapy, NK Cells, Mesenchymal Stromal Cells, Immuno-oncology, and Osteoarthritis

582 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Technology-driven biotech with an AI-powered miniprotein RnD platform VRG Tx is technology-driven biotech with a drug discovery platform that integrates AI with wet lab processes to develop next-generation therapeutics. Our vision is to cure diseases through previously undruggable targets and inaccessible mechanisms of action. medicinal biotechnology, research, immunology autoimmune deases , translational health research, use of genetic engineering in medicine, anti cancer drug discovery, oncological drugs, autoimmune diseases, translational research, peptide, cellandgenetherapy, and genetherapy

589 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Nonclinical expert in cardiovascular pharmacology & electrophysiology and vascular functions PhysioStim is a French preclinical CRO dedicated to cardiovascular pharmacology and electrophysiology from discovery stages to clinical development. Whatever the therapeutic areas, we ensure robust and valuable preclinical data on cardiac and vascular activities and secondary pharmacology to secure in-vivo development and bring new safe therapies to patients. Thanks to our predictive and translational models, we define the POC of drug discovery, we investigate secondary pharmacology with on and off-target liabilities, and we address the safety purpose to build and support your IND submission (with mandatory and not mandatory assays). …

123 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Innovating to Disrupt Cancer Treatment Genoscience Pharma is a French biotech company developing unique small molecules in Oncology. This is the first clinical stage company ever with unique lysosomotropic agents assessed in global clinical trials. For more information, please visit our website, or call us +33 4 91 26 99 50. Liver, Oncology, Clinical Development, Preclinical Development, Discovery, Research & Development, Intellectual Property, Drug Development, and Small Molecule

634 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Preclinical expertise in cardiovascular pharmacology for 25+ years. in vitro & in vivo services, by ETAP-LAB. SYNCROSOME by ETAP-LAB, preclinical services supporting therapeutic innovations for over 25 years Part of ETAP-LAB, a recognized European preclinical CRO delivering efficient, cost-effective services to pharmaceutical, biotech/medtech, and nutraceutical companies across four key areas: • SYNCROSOME – Cardiovascular & cardiorespiratory pharmacology, with 25+ years of international expertise. • BRAINXPLORE – Expert in neurology and CNS disorders with integrated preclinical solutions for neurodegeneration and behavioral pharmacology. ​​ • SKINAXIS – Pharmacology efficacy in dermatology and skin disorders – supporting the development of drugs, regenerative therapies, …

125 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

miRNA-enhanced Extracellular Vesicles Therapeutics ConvEyXO, founded in 2019 by veterans of pharma industry, builds a specialized technology platform to convey exosome-based therapeutics to the market. The company is developing is therapeutic portfolio in the field of fibrosis and chronic inflammatory disorders. The rapid development of the company is the result of collaborations with partners with a demonstrated track record in healthtech and biotech fields manufacturing, process development, upstream, downstream, extracellular vesicles, exosomes, therapeutics, cargo, Loading, 4D, and exosomes

444 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Powering the future of medicine® We support the advancement of cell and gene therapies through our portfolio of cytokines and media supplements, along with a comprehensive suite of manufacturing services—including the production of proteins, media and buffers, and transfection and transduction reagents. We ensure your raw materials are as innovative as your therapies. GMP cytokines, Crypreservation media, Hemaotopietic and Mesechymal Cells and sources, Sterile Fill & Finish, Media & Buffers, Transfection Reagents, Human Plasma Derived Products, and Growth Factors

181 similar entities Type: SMB Activities: deeptech manufacturing biotech Technologies: Synthetic Biology

Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to provide innovative, tailored solutions spanning preclinical research, translational platforms, and clinical trial support. With the world’s largest commercially available patient-derived xenograft (PDX) collection and approximately 1,000 tumor organoid models powered by Hubrecht Organoid Technology, we offer unparalleled insights across 35 cancer indications. Our expertise spans in vivo, in vitro, ex vivo, and in silico methods, complemented by advanced laboratory services that span the entire drug development continuum. …

437 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

A Next Generation Stem Cell Therapeutics Company Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on CymerusTM, a proprietary therapeutic stem cell platform technology. CymerusTM overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors. Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for …

60 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology